This guideline consolidates all previous updates and reflects the body of evidence informing this guideline topic. Ten new RCTs were identified in the latest search of the literature to date.

Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer The search strategy identified 257 ...

Early-Onset Colorectal Cancer Survival Differences and Potential Geographic Determinants Among Men and Women in Utah Artificial intelligence in oncology is no longer hypothetical, and its U.S. Food ...

Electronic Nicotine Delivery Systems and Tobacco Control in Low- and Middle-Income Countries: Local Cancer Care Institutions Need to Do More Despite these advancements, Morocco, like other African ...

Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study ...

American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange: From Inception to First Data Release and Beyond—Lessons Learned and Member Institutions’ Perspectives ...

Of the 117 patients enrolled, 116 completed chemotherapy, with the median age of 32 years: 50% men, 98% stage II, 86% Memorial Sloan Kettering–defined disease bulk, 27% traditional bulk (> 10 cm), 52% ...

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group A total of 191 patients (modified ...

Nasopharyngeal carcinoma (NPC) is a unique head and neck cancer with an extremely uneven geographic global distribution. Although NPC is fairly uncommon in many jurisdictions, it remains a significant ...

Prospective Study of Supplemental Screening With Contrast-Enhanced Mammography in Women With Elevated Risk of Breast Cancer: Results of the Prevalence Round In a tumor agnostic fashion, cfDNA for ...

Cancer Care Ontario (CCO; now a division of Ontario Health [OH]) and ASCO published a joint guideline in 2017 on the use of adjuvant bisphosphonates and other bone-modifying agents (BMAs) in breast ...